Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories
- PMID: 15970877
- DOI: 10.1016/j.ajog.2005.03.034
Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories
Abstract
Objective: This study was undertaken to investigate whether amphotericin B vaginal suppositories would be effective in the treatment of non- albicans Candida vaginitis in women who failed conventional therapy.
Study design: Thirty-two patients were identified with non- albicans Candida vaginitis. These patients were treated with conventional antifungal agents. Ten patients had persistence of the non- albicans Candida infection after treatment. Amphotericin B 50-mg vaginal suppositories were given nightly for 14 days to this subgroup of treatment failures.
Results: Of 10 women, 8 (80%) who were treated with amphotericin B vaginally initially showed no further infection. One of the treatment successes had 2 recurrences and responded to a second course of amphotericin B but failed a third course. If this patient is considered a treatment failure, then amphotericin B vaginal suppositories were successful in 70% of patients. The medication was well tolerated and local side effects were minimal.
Conclusion: Amphotericin B vaginal suppositories are a viable treatment option for refractory vaginitis caused by non- albicans Candida .
Similar articles
-
Prevalence and management of non-albicans vaginal candidiasis.Sex Transm Infect. 2010 Apr;86(2):99-100. doi: 10.1136/sti.2009.040386. Sex Transm Infect. 2010. PMID: 20332368
-
Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.Infect Dis Obstet Gynecol. 2000;8(5-6):240-3. doi: 10.1155/S1064744900000351. Infect Dis Obstet Gynecol. 2000. PMID: 11220485 Free PMC article.
-
Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.Diabetes Care. 2007 Feb;30(2):312-7. doi: 10.2337/dc06-1469. Diabetes Care. 2007. PMID: 17259500 Clinical Trial.
-
Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.J Womens Health (Larchmt). 2011 Aug;20(8):1245-55. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20. J Womens Health (Larchmt). 2011. PMID: 21774671 Review.
-
[Fungal diseases of vulva and vagina caused by Candida species].Med Monatsschr Pharm. 2010 Sep;33(9):324-33; quiz 335-6. Med Monatsschr Pharm. 2010. PMID: 21192442 Review. German.
Cited by
-
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.Mycopathologia. 2023 Apr;188(1-2):99-109. doi: 10.1007/s11046-022-00687-w. Epub 2022 Nov 15. Mycopathologia. 2023. PMID: 36378354
-
Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.Antimicrob Agents Chemother. 2012 Mar;56(3):1403-6. doi: 10.1128/AAC.05025-11. Epub 2012 Jan 9. Antimicrob Agents Chemother. 2012. PMID: 22232293 Free PMC article.
-
An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis.J Fungi (Basel). 2018 Oct 31;4(4):121. doi: 10.3390/jof4040121. J Fungi (Basel). 2018. PMID: 30384449 Free PMC article. Review.
-
Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods.J Clin Med. 2023 Aug 18;12(16):5376. doi: 10.3390/jcm12165376. J Clin Med. 2023. PMID: 37629418 Free PMC article. Review.
-
Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).Geburtshilfe Frauenheilkd. 2015 Apr;75(4):342-354. doi: 10.1055/s-0035-1545741. Geburtshilfe Frauenheilkd. 2015. PMID: 27065484 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources